Stock

ADXN

Addex Therapeutics Ltd.

0 of 27 marquee funds currently hold1 CUSIP mapped

Current holders

27 funds tracked

Ever held

Current + past

New this quarter

Exited this quarter

Marquee-fund ownership over time

Feb 14, 2025Aug 14, 2025

Now

Past holders

Funds that exited at some point

Fund	Last entry	Exited	Entry → Exit	Return
Citadel Advisors	Q1 2025	Q3 2025	—	+0%

Fundamentals

XBRL · Addex Therapeutics Ltd.

Not enough XBRL history to plot. Addex Therapeutics Ltd.hasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Addex Therapeutics Ltd. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds

Fund	Open date	Close date	Open price	Close price / current	Return
Citadel Advisors	Q1 2025	Q3 2025	$0.00	—	+0%

Caveats

Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
“Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.